Natural products targeting amyloid beta in alzheimer’s disease

Joo Hee Lee, Na Hyun Ahn, Su Bin Choi, Youngeun Kwon, Seung Hoon Yang

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by severe brain damage and dementia. There are currently few therapeutics to treat this disease, and they can only temporarily alleviate some of the symptoms. The pathogenesis of AD is mainly preceded by accumulation of abnormal amyloid beta (Aβ) aggregates, which are toxic to neurons. Therefore, modulation of the formation of these abnormal aggregates is strongly suggested as the most effective approach to treat AD. In particular, numerous studies on natural products associated with AD, aiming to downregulate Aβ peptides and suppress the formation of abnormal Aβ aggregates, thus reducing neural cell death, are being conducted. Generation of Aβ peptides can be prevented by targeting the secretases involved in Aβ‐peptide formation (secretase‐dependent). Additionally, blocking the intra‐ and intermolecular interactions of Aβ peptides can induce conformational changes in abnormal Aβ aggregates, whereby the toxicity can be ameliorated (structure‐dependent). In this review, AD‐associated natural products which can reduce the accumulation of Aβ peptides via secretase‐ or structure‐dependent pathways, and the current clinical trial states of these products are discussed.

Original languageEnglish
Article number2341
Pages (from-to)1-17
Number of pages17
JournalInternational Journal of Molecular Sciences
Volume22
Issue number5
DOIs
StatePublished - 1 Mar 2021

Keywords

  • Alzheimer’s disease
  • Amyloid beta
  • Natural products
  • Secretase‐dependent
  • Structure-dependent

Fingerprint

Dive into the research topics of 'Natural products targeting amyloid beta in alzheimer’s disease'. Together they form a unique fingerprint.

Cite this